Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Barr Pharmaceuticals and Iceland's Actavis Group continue to battle for control of Croatian drug firm Pliva. In the latest development, Barr has matched the $2.5 billion offer made by Actavis in August. The saga began in March, when Actavis made Pliva an unsolicited $1.6 billion bid, which was later sweetened to $1.9 billion. Barr came into the picture in June, when it made a $2.2 billion offer for the firm. Though Pliva appears to be favoring Barr, Actavis has not given up, causing the price tag to creep up over the past six months.
This article has been sent to the following recipient: